Skip to main
RXST

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 0%
Hold 67%
Sell 22%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated a strong financial performance with a revenue increase that surpassed consensus expectations and an upward revision of its guidance, indicating robust operational execution. The company is anticipated to sustain double-digit growth fueled by increased utilization of its light adjustable lenses (LDD) and an expanding installed base, as emphasized by management's strategic initiatives. Additionally, RxSight's improved gross margin guidance for 2025 reflects operational efficiencies and positions the company for potential upside through further market penetration and enhanced volume growth.

Bears say

RxSight Inc. is experiencing declining utilization rates and LDD placements, with a notable drop to 8.0 LALs per LDD in 3Q25, down from 8.7 in the prior quarter and 10.1 a year earlier, indicating challenges in customer adoption. Additionally, the company's revenue decreased by 14% year-over-year to $30.3 million, alongside a significant 68% year-over-year reduction in the placement of Light Delivery Devices (LDDs) in 2Q25, highlighting disappointing commercial execution. Furthermore, risks such as increased competition in the intraocular lens market, dependence on capital equipment for adoption, and potential dilutive financing could negatively impact future growth prospects.

RxSight (RXST) has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 9 analysts, RxSight (RXST) has a Hold consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.